PowderMed, an immunotherapeutic product company, engaged in the development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company’s immunotherapeutic products are delivered using its proprietary DNA-particle mediated epidermal delivery technology.

Based in Oxford, United Kingdom, the Company was founded in 2004 and was acquired by Pfizer in December 2006.